#1
|
|||
|
|||
Âèðóñíûé êîíúþíêòèâèò
Çäðàâñòâóéòå!
Ðåáåíîê áîëååò êàæäóþ âåñíó è îñåíü âìåñòå ñî ìíîé àäåíîâèðóñíûì êîíúþíêòèâèòîì (òàêîé äèàãíîç ñòàâèò âðà÷- îôòàëüìîëîã). Ïðè ýòîì ó ìåíÿ ñ ðåáåíêîì òàêæå åñòü íåáîëüøîé íàñìîðê, êàøåëü. ß äóìàþ, ÷òî ïðèíîñèò âèðóñ èç ñàäà. Ñûíó 4,5 ãîäà, ðàíüøå áîëåë î÷åíü ÷àñòî ÎÐÂÈ â ÿñëÿõ. Ñåé÷àñ â îñíîâíîì îäèí êîíúþíêòèâèò íîñèò. Áûâàåò áîëåçíü ðàñòÿãèâàåòñÿ íà ìåñÿö- ïîëòîðà. Õîòåëà áû ñïðîñèòü ó âàñ, óâàæàåìûå âðà÷è: 1. Ñóùåñòâóåò ëè êàêàÿ- íèáóäü ïðîôèëàêòèêà ïðîòèâ ýòîãî âèðóñà? 2. Ïî÷åìó âèðóñ â ãëàçàõ íå ïðîõîäèò ñàì ïî ñåáå è îáÿçàòåëüíî êàæäûé ðàç ìû êàïàåì îôòàëüìîôåðîí, àíòèáèîòèêè, òàê êàê ÷àñòî "êðàñíûå ãëàçà" ñî÷åòàþòñÿ ñ ãíîåì. Ìíå ýòî íå ïîíÿòíî, ïîòîìó ÷òî ëþáîå ÎÐÂÈ ó ÷åëîâåêà ïðîõîäèò ñàìî ïî ñåáå çà íåñêîëüêî äíåé, à òóò âñå ïî- äðóãîìó. 3. Âûðàáàòûâàåòñÿ ëè êàêîé- íèáóäü èììóíèòåò ïîñëå ïåðåíåñåííîãî êîíúþíêòèâèòà? Åñòü ëè íàäåæäà, ÷òî ýòî êîãäà- íèáóäü ïðåêðàòèòñÿ? Íà äàííûé ìîìåíò ðåáåíîê çäîðîâ. Ïðîêàïàëè îôòàëüìîôåðîí 5 äíåé ïî 8 ðàç â äåíü è 7 äíåé ëåâîìèöèòèí ïî 6 ðàç â äåíü. À ó ìåíÿ òàê è íå ïðîøåë, õîòÿ ÿ êàïàëà îôòàëüìîôåðîí 10 äíåé (íà ñåãîäíåøíèé äåíü) è ëåâîìèöåíòèí. ![]() ß ñîâñåì óæå çàïóòàëàñü ñ ýòèì êîíúíêòèâèòîì. Áóäó î÷åíü ïðèçíàòåëüíà, åñëè ïðîÿñíèòå äëÿ ìåíÿ ñèòóàöèþ. ![]() |
#2
|
|||
|
|||
Çäðàâñòâóéòå. Èíôèëüòðàòû íà ðîãîâèöå (òî÷å÷íûå èëè ìîíåòîâèäíûå), ê ñîæàëåíèþ, õàðàêòåðíû äëÿ àäåíîâèðóñíîãî êåðàòîêîíúþíêòèâèòà. Ëå÷åíèå àäåíîâèðóñíîãî êîíúþíêòèâèòà îôòàëüìîôåðîíîì è ëåâîìèöåòèíîì ìîæíî ñ÷èòàòü àäåêâàòíûì. ×òî äåëàòü ñ ÷àñòûìè ÎÐÂÈ (âåäü, ñóäÿ ïî âàøèì ñëîâàì - ýòî ïåðâîïðè÷èíà êîíúþíêòèâèòà) Âàì ëó÷øå ïîèíòåðåñîâàòüñÿ ó òåðàïåâòîâ è èíôåêöèîíèñòîâ (ñîçäàéòå òàì òåìó ñ âîïðîñîì î âîçìîæíûõ ïóòÿõ ïðîôèëàêòèêè ÎÐÂÈ).
Ñ óâàæåíèåì, Äàðèíà. |
#3
|
|||
|
|||
Ñïàñèáî çà îòâåò!
À ñêîëüêî ïðèìåðíî ïî âðåìåíè íóæíî ëå÷èòü îôòàëüìîôåðîíîì àäåíîâèðóñ, ÷òîáû óæ òî÷íî áûòü óâåðåííîé, ÷òî âèðóñà â ãëàçàõ íåò? 10-14 äíåé äîñòàòî÷íî? Ïî ïîâîäó èíôèëüòðàòîâ: ðàññàñûâàþòñÿ îíè ñàìè èëè ìîãóò îñòàâëÿòü êàêèå òî íåîáðàòèìûå èçìåíåíèÿ íà ðîãîâèöå?  áóäóùåì õîòåëà áû ñäåëàòü ËÀÑÈÊ ñåáå. Áîþñü, ÷òî ýòîò àäåíîâèðóñ èëè åãî ïîñëåäñòâèÿ ìîãóò ïîìåøàòü ìíå ![]() |
#4
|
|||
|
|||
Âðåìÿ ëå÷åíèÿ èíäèâèäóàëüíî. Èíîãäà äîñòàòî÷íî è 5 äíåé, à èíîãäà íóæíî áîëüøå. Âñå çàâèñèò îò êëèíèêè, à îíà îïðåäåëÿåòñÿ Âàøèìè ñóáúåêòèâíûìè îùóùåíèÿìè è î÷íûì îñìîòðîì îôòàëüìîëîãà. Ñ èíôèëüòðàòàìè òîæå èíäèâèäóàëüíî - ÷àùå ðàññàñûâàþòñÿ, íî èíîãäà, åñëè ðàñïîëàãàþòñÿ ãëóáæå ýïèòåëèÿ ðîãîâèöû - ìîãóò è îñòàòüñÿ â âèäå íåæíûõ ïîìóòíåíèé (íà îñòðîòó çðåèÿ îáû÷íî ñèëüíî íå âëèÿþò). Íàñ÷åò ËÀÑÈÊ - òîæå èíäèâèäóàëüíî. Íî ïîêà íå íàñòóïèò äëèòåëüíûé ïåðèîä ðåìèññèè î ëàçåðíîé êîððåêöèè äóìàòü ðàíî.
Ñ óâàæåíèåì, Äàðèíà. |
#5
|
||||
|
||||
Öèòàòà:
Ëåâîìèöåòèí... íåò åãî â ðåêîìåíäàöèÿõ, ðóêîâîäñòâàõ ïî âåäåíèþ êîíúþêòèâèòîâ.  ñëó÷àå âèðóñíûõ, òåì áîëåå. Äëÿ âðà÷åé. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ïðè íîðìàëüíîì ñòå÷åíèè îáñòîÿòåëüñòâ áàêòåðèàëüíûé êîíúþêòèâèò ïðîõîäèò ñàìîñòîÿòåëüíî çà 2 íåäåëè. Ëå÷åíèå è èìåííî áîëåå áûñòðîå âûçäîðîâëåíèå íåîáõîäèìî ñ öåëüþ íåäîïóùåíèÿ çàðàæåíèÿ äðóãèõ/äåòÿì íå ïðîïóñêàòü øêîëó/èõ ðîäèòåëÿì ðàáîòó. Íà ñåãîäíÿøíèé äåíü íåò îäíîçíà÷íîãî ìíåíèÿ, íàçíà÷àòü ëè ÀÁ ñðàçó, èñõîäÿ èç äàííûõ ïîñëåäíèõ èññëåäîâàíèé (òðèàëîâ) áîëåå ñêëîíÿþòñÿ, åñëè è íàçíà÷àòü ÀÁ òî ñ îòñðî÷êîé â íåñêîëüêî äíåé.[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ïðè èìåþùèõñÿ ïîêàçàíèÿõ ê íàçíà÷åíèþ àíòèáèîòèêà âûáîð îíîãî îïðåäåëÿåòñÿ ñëåäóþùèìè êðèòåðèÿìè: àäåêâàòíîñòü ïðè íàçíà÷åíèè ÀÁ (íå âñåì ïîäðÿä) è ïðàâèëüíûé âûáîð (ìàêñèìàëüíîå ïîêðûòèå ñïåêòðà áàêòåðèé, îòñóòñòâèå ðåçèñòåíòíûõ øòàììîâ). Ïðåäñòàâëÿåòñÿ âîçìîæíûì èñïîëüçîâàíèå êàïåëü ôòîðõèíîëîíîâ 2 ïîêîëåíèÿ, îôëîêñàöèíà èëè öèïðîôëîêñàöèíà, èëè áîëåå íîâîãî ïîêîëåíèÿ. Òàêæå, âûñîêî ýôôåêòèâíû êàïëè ñ àçèòðîìèöèíîì, îäíàêî íå óâåðåí, ÷òî åñòü â Ðîññèè.[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#6
|
|||
|
|||
Öèòàòà:
À ÷òî òîãäà íóæíî, åñëè ãëàçà ïðè ýòîì åëå îòêðûâàþòñÿ, ÷åøóòñÿ, òå÷åò ñëèçü, è ÷àùå âñåãî èäåò åùå è ãíîé? Îôòàëüìîôåðîí äåéñòâèòåëüíî î÷åíü ïîìîãàåò, ïðàâäà, âîçìîæíî, òîëüêî ñíèìàåò ñèìïòîìàòèêó.  íåì êðîìå èíòåðôåðîíà ñîäåðæèòñÿ,íàïðèìåð, åùå äèìåäðîë, áîðíàÿ êèñëîòà è ò.ä. Åñëè íå îôòàëüìîôåðîí, òî ÷åì òîãäà õîòÿ áû îáëåã÷èòü ñîñòîÿíèå ãëàç ïðè ýòîì? |
#7
|
||||
|
||||
Ñîððè, âñå íàïèñàíî âûøå. Òî, ÷òî ïîìîãàåò, èëè Âàì êàæåòñÿ... ýòî äâå áîëüøèå ðàçíèöû. Ïîïðîáóéòå îáû÷íûé ôèçðàñòâîð, âîçìîæíî ýôôåêò áóäåò òîò æå. Î ïîêàçàíèÿõ è ðåæèìå äîçèðîâàíèÿ àíòèáèîòèêîâ, òàêæå íàïèñàíî. Ïðåïàðàò ñ ýòèì ñîñòàâîì, íå äîëæåí íàçíà÷àòüñÿ íè äåòÿì íè âçðîñëûì.
Öèòàòà:
|
|
#9
|
|||
|
|||
Vadimbondar, à êàê Âû îòíîñèòåñü ê îôòàëüìîôåðîíó? Âû òîæå ñ÷èòàåòå, ÷òî åãî íåëüçÿ ïðèìåíÿòü íè äåòÿì, íè âçðîñëûì?
![]() Öèòàòà:
|
#10
|
|||
|
|||
Óâàæàåìûå êîëëåãè. Ðàçðåøèòå ñ Âàìè ïîñïîðèòü íàñ÷åò ëå÷åíèÿ âèðóñíûõ êîíúþíêòèâèòîâ ôèç. ðàñòâîðîì. Ñïîðèòü áóäó ñ ïîìîùüþ ññûëêè
![]() [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Âîò òîëüîê âûäåðæêà , ïîëíîñòüþ ìîæåòå îçíàêîìèòüñÿ ïî ññûëêå... Medications used in the treatment of viral conjunctivitis include the following: topical artificial tears, 4-8 times per day, for 1-3 weeks; topical vasoconstrictor/antihistamine, 4 times per day, for severe itching; topical steroids for pseudomembranes and subepithelial infiltrates; topical antibiotic to prevent bacterial superinfection; topical antiviral agents for HSV infection; and oral acyclovir for VZV infection. Drug Category: Ocular lubricants Used for symptomatic relief. Drug Name Artificial tears (Refresh, Celluvisc, Murine) Description Act to stabilize and thicken precorneal tear film and prolong tear film breakup time, which occurs with dry eye states. Adult Dose 1-2 gtt 4-8 times/d; may use more frequently if preservative free Pediatric Dose Administer as in adults Contraindications Documented hypersensitivity Interactions None reported Pregnancy A - Safe in pregnancy Precautions Hyperemia, photophobia, stickiness of eyelashes, and ocular discomfort or irritation may occur Drug Category: Antihistamines Used to treat severe itching. Drug Name Levocabastine (Livostin) Description Potent histamine H1-receptor antagonist; for ophthalmic use. Adult Dose 1 gtt in each affected eye qid Pediatric Dose <12 years: Not established >12 years: Administer as in adults Contraindications Documented hypersensitivity Interactions None reported Pregnancy C - Safety for use during pregnancy has not been established. Precautions Shake well prior to use; not for internal (systemic) use; avoid use of contact lenses while on medication Drug Category: Corticosteroids For pseudomembranes and decreased vision and/or glare due to subepithelial infiltrates. Have anti-inflammatory properties and cause profound and varied metabolic effects. In addition, these agents modify the body's immune response to diverse stimuli. Drug Name Prednisolone (AK-Pred, Pred Forte) Description Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing increased capillary permeability. Less potent (eg, prednisolone 0.125%, fluorometholone 0.1%) are usually sufficient to treat subepithelial infiltrates. The steroid must be tapered very slowly, over months. Adult Dose 1 gtt q1-6h, depending on severity of infection; taper slowly over several d to wk Pediatric Dose Administer as in adults Contraindications Documented hypersensitivity; HSV keratitis; acute viral keratitis; VZV; suspected fungal keratitis; mycobacterial infection; glaucoma Interactions None reported Pregnancy C - Safety for use during pregnancy has not been established. Precautions Caution in patients with glaucoma; corticosteroids are associated with increased intraocular pressure and cataract in some patients; they may worsen certain infections, such as from herpes simplex, bacteria, and fungi Drug Category: Antivirals Used for the treatment of HSV infection. Drug Name Trifluridine (Viroptic) Description Pyrimidine (thymidine) analogue DOC in the United States for topical antiviral therapy for HSV infection. Inhibits viral replication by incorporating into viral DNA in place of thymidine. If no response in 7-14 d, consider other treatments. Adult Dose 1 gtt into affected eye q2h while awake; not to exceed 9 gtt/d for 10 d, not to exceed 21 d; taper thereafter Pediatric Dose Administer as is adults Contraindications Documented hypersensitivity Interactions None reported Pregnancy C - Safety for use during pregnancy has not been established. Precautions All topical antiviral medications currently available for clinical use in the United States are toxic; adverse reactions include discomfort upon instillation and palpebral edema, irritation, and superficial punctate or epithelial keratopathy Drug Name Acyclovir (Zovirax) Description Prodrug activated by phosphorylation by virus-specific thymidine kinase that inhibits viral replication. Adult Dose Herpes zoster ophthalmicus: 800 mg PO 5 times/d for 7-10 d Recurrent episodes: 400-800 mg PO bid for 7-10 d; initiate treatment immediately upon onset of symptoms of recurrent episodes Prevention of herpes simplex infections: 400 mg PO bid, can be used to prevent recurrent herpes simplex infections and inflammations Pediatric Dose 20 mg/kg/dose PO q6h up to a maximum of 800 mg Contraindications Documented hypersensitivity; caution in renal disease Interactions Concomitant use of probenecid or zidovudine prolongs half-life and increases CNS toxicity of acyclovir Pregnancy B - Usually safe but benefits must outweigh the risks. Precautions Caution in renal failure or when using nephrotoxic drugs Ñ óâàæåíèåì, Äàðèíà. |
#11
|
|||
|
|||
 ïðîäîëæåíèå äèñêóññèè âûëîæó åùå äâå ññûëêè, îíè, êîíå÷íî íå ïðî îôòàëüìîôåðîí (òàêîãî ïðåïàðàòà íà Çàïàäå íåò), íî àíòèãèñòàìèíû è àíòèáèîòèêè äëÿ ïðîôèëàêòèêè íàñëîåíèÿ âòîðè÷íîé áàêòåðèàëüíîé èíôåêöèè, è êðîìå òîãî, ñîîáùåíèÿ î ëå÷åíèè ðèáàâèðèíîì è öèäîâèðîì â íèõ ïðèñóòñòâóþò.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Pharyngoconjunctival Fever [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Adenovirusesâûäåðæêà... Currently, specific therapy for adenovirus infection, other than supportive and symptomatic treatment, remains a matter of debate. Òàê ÷òî íå ñîâñåì âñå îêîí÷àòåëüíî ÿñíî ñ ýòèì âîïðîñîì. Òåì áîëåå, ÷òî áóäó÷è ïðàêòè÷åñêèì îôòàëüìîëîãîì, ÷àñòî ïðèíèìàþ ïàöèåíòîâ ñ àäåíîâèðóñíûì êîíúþíêòèâèòîì, êîòîðûå äâå íåäåëè äóìàëè, ÷òî âñå ïðîéäåò è òàê (÷àåì ïðîìûâàëè ãëàçà). À ðåçóëüòàò - èíôèëüòðàòû íà ðîãîâèöå è íàñëîåíèå âòîðè÷íîé áàêòåðèàëüíîé èíôåêöèè. Ñ óâàæåíèåì, Äàðèíà. |
#12
|
||||
|
||||
Êîëëåãà, äàííûé ðåñóðñ, â ïðèíöèïå íå ïîñëåäíèé èñòî÷íèê, î áîëüøîì êîëè÷åñòâå ëÿïîâ êîòîðîãî, íàïðèìåð, íå ðàç ïèñàëà ßíà, è íå ðàç îáñóæäàëîñü - èñïîëüçîâàòü ìîæíî, íî â êà÷åñòâå îçíàêîìëåíèÿ. Ñêîðåå äëÿ ìëàäøåãî çâåíà, íåñïåöèàëèñòîâ. ß, íàïðèìåð, êàê íåñïåöèàëèñò â îáëàñòè îôòàëüìîëîãèè ìîãó îçíàêîìèòüñÿ ñ ïðèíöèïàìè ëå÷åíèÿ êåðàòîêîíúþêòèâèòîâ, èëè èðèäîöèêëèòîâ, íå áîëåå.
Íî ïîñìîòðèì, ÷òî Âû ïðåäñòàâèëè. Èç ïåðâîé Âàøåé ññûëêè [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Öèòàòà:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Currently, specific therapy for adenovirus infection, other than supportive and symptomatic treatment, remains a matter of debate. * Several case reports of successes with ribavirin therapy have been cited for serious adenoviral disease in immunocompromised patients; however, the number of failed treatments that have not been reported remains uncertain. No available studies adequately address issues such as which syndromes are most likely to respond to treatment, which patients develop limiting hematologic toxicity from ribavirin or nephrotoxicity from cidofovir, or which patients, if any, may benefit from adjunctive therapy with leukocyte transfusions. Fortunately, most infections are self-limited in the setting of a normal immune response and do not warrant specific therapy. |
#13
|
||||
|
||||
Èòàê, âñå ïðèâåäåííûå Âàìè ìàòåðèàëû, Äàðèíà, ñâèäåòåëüñòâóþò îá îäíîì - âñå íà ýêñïåðèìåíòàëüíîì óðîâíå. Ðèáàâèðèí è Ñèäîôîâèð ñêîðåå îáëàäàþò áîëåå òÿæêèìè ïîáî÷êàìè, íåæåëè ëå÷åáíûì ýôôåêòîì. Óïîìÿíóòûé èíòåðôåðîí, âî ïåðâûõ îòëè÷àåòñÿ îò "îôòàëüìîôåðîíà" íî è îïÿòü æå íåò èíôîðìàöèè, äîêàçàòåëüñòâ ýôôåêòèâíîñòè.
ß íå äóìàþ, ÷òî ñòàâèòü ýêñïåðèìåíòû íàä ëþäüìè ýòî ýòè÷íî, èëè ïðîñòî õîðîøî. Âàø êëèíè÷åñêèé îïûò, ðàâíî êàê è ìîé, îòäåëüíî âçÿòûå íå ìîãóò ðàññìàòðèâàòüñÿ â êà÷åñòâå êàêèõ ëèáî äîêàçàòåëüñòâ. Ýòî "ïèööîò" ðàç îáñóæäàëîñü â ñòåíàõ ÐÌÑ. Äàâàéòå îáðàòèìñÿ ê ðóêîâîäñòâàì: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Öèòàòà:
Çäåñü ìîæíî íàéòè ðóêîâîäñòâà ïî ìíîãèì íîçîëîãèÿì ãëàçíûõ áîëåçíåé. Ï.Ñ. Ñîððè, ïðèâåë îòäåëüíûå ñòàòüè íà àíãëèéñêîì, áåç ïåðåâîäà, òàê êàê èäåò îáñóæäåíèå âðà÷åáíîãî àñïåêòà, íå äëÿ ïàöèåíòà. |
#14
|
|||
|
|||
Íî âñå-òàêè àíòèãèñòàìèíû íå èñêëþ÷àþòñÿ?
Ðå÷ü íå èäåò î íåýòè÷íîñòè, ìû íå ãîâîðèì î êàêèõ-òî íîâûõ íåèññëåäîâàííûõ íà ëþäÿõ ïðåïàðàòàõ. Ðå÷ü èäåò î òîì, ÷òî ôèç. ðàñòâîð íå ñàìîå ëó÷øåå ñðåäñòâî äëÿ ëå÷åíèÿ òÿæåëûõ àäåíîâèðóñíûõ êåðàòîêîíúþíêòèâèòîâ. Ñ óâàæåíèåì, Äàðèíà. |